What is DNA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.88B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DNA?

P/E (TTM) is n/a and 52-week range is $5.37 to $18.22 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DNA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DNA?

The company profile lists revenue (TTM) near $112M, net income (TTM) near $-29.19B, EPS (TTM) near $-5.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ginkgo Bioworks Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 62.3M shares outstanding, ISIN US37611X2099 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Ginkgo Bioworks Holdings Inc (DNA) Stock Analysis & Quote

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. The company is headquartered in Boston, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Employees

485

Website

investors.ginkgobioworks.com/

IPO

2021-04-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)